The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial

Inclusion Criteria:

• Signed written informed consent.

• Men or women at least 18 years old (in Taiwan, at least 20 years old). Women must bepost-menopausal or using a highly effective method for avoidance of pregnancy.

• Hospitalization for acute coronary syndrome (ACS) within 30 days prior to study entry.

• Clinically stable for 24 hours prior to study entry.

• A planned percutaneous coronary intervention (PCI) should be performed prior to studyentry, whenever possible.

• At least one of the following:

• At least 60 years old.

• Myocardial infarction prior to the qualifying ACS event.

• Diabetes mellitus requiring treatment with medication.

• Diagnosed mild or moderate reduction in kidney function.

• Cerebrovascular disease (carotid artery disease or ischemic stroke more than 3 monthsprior to study entry) OR peripheral artery disease.

Exclusion Criteria:

• ACS symptoms or lab results not believed to be caused by a narrowing or blockedcoronary artery.

• No major coronary artery with a blockage of more than 50% (unless all stenoses aresuccessfully treated by PCI).

• Planned coronary artery bypass graft (CABG) surgery, or CABG surgery performed afterthe qualifying ACS event and prior to study entry.

• Certain types of liver disease.

• Severe reduction in kidney function OR removal of a kidney OR kidney transplant.

• Severe heart failure.

• Blood pressure higher than normal despite lifestyle changes and treatment withmedications.

• Any life-threatening disease with a life expectancy of less than 2 years (other thanheart disease) that may prevent the subject from completing the study.

• Severe asthma that is poorly controlled with medication.

• Pregnancy (Note: A pregnancy test will be performed on all non-sterile women prior tostudy entry).

• Previous severe allergic reaction to food, medications, drink, insect stings, etc.

• Drug or alcohol abuse within the past 6 months. Mental/psychological impairment thatmay prevent the subject from complying with study procedures or understanding the goaland potential risks of participating in the study.

• Certain medications that may interfere with the study medication (these will beidentified by the study doctor).

• If both birth parents are at least 50% Japanese, Chinese, or Korean ancestry, musthave a blood sample collected for Lp-PLA2 activity. Those with Lp-PLA2 activity lessthan or equal to 20.0 nmol/min/mL are excluded.

• Previously took darapladib (SB-480848).

• Participation in a study of an investigational medication within the past 30 days.

• Current participation in a study of an investigational device.

• Any other reason the investigator deems the subject should not participate in thestudy.